Kenvue (KVUE) plans to appoint Jon Halvorson as chief marketing officer amid a public relations crisis regarding claims linking Tylenol and autism, The Wall Street Journal’s Suzanne Vranica reports. People familiar with the matter say the appointment of Halvorson, who spent the past eight years at Mondelez (MDLZ), is expected to be made official in coming days. President Trump and Health Secretary Robert F. Kennedy Jr. issued a warning last month that acetaminophen, the active ingredient in Tylenol, is a potential cause of autism, while on Tuesday, Texas AG Ken Paxton filed a lawsuit accusing Kenvue of deceptive advertising.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Hold Rating for Kenvue, Inc.: Legal Challenges and Sales Decline Amidst Growth Potential
- Citi says headlines could push consumers to alternatives to Kenvue’s Tylenol
- Texas AG’s Tylenol Lawsuit Rattles Kenvue Stock (KVUE)
- Texas sues Kenvue, Johnson & Johnson over Tylenol autism risk